| Year |
Citation |
Score |
| 2021 |
Fritzwanker S, Moulédous L, Mollereau C, Froment C, Burlet-Schiltz O, Effah F, Bailey A, Spetea M, Reinscheid RK, Schulz S, Kliewer A. HA-MOP knockin mice express the canonical µ-opioid receptor but lack detectable splice variants. Communications Biology. 4: 1070. PMID 34522000 DOI: 10.1038/s42003-021-02580-6 |
0.728 |
|
| 2020 |
Talmont F, Veneziano R, Dietrich G, Moulédous L, Mollereau C, Zajac JM. Pharmacological insight into the activation of the human neuropeptide FF2 receptor. Peptides. 134: 170406. PMID 32920044 DOI: 10.1016/J.Peptides.2020.170406 |
0.765 |
|
| 2016 |
Mudgal A, Kumar K, Mollereau C, Pasha S. NPYFa a chimeric peptide of Met-enkephalin and NPFF, induces tolerance free analgesia. Chemical Biology & Drug Design. PMID 26802437 DOI: 10.1111/cbdd.12721 |
0.557 |
|
| 2015 |
Moulédous L, Froment C, Burlet-Schiltz O, Schulz S, Mollereau C. Phosphoproteomic analysis of the mouse brain mu-opioid (MOP) receptor. Febs Letters. 589: 2401-8. PMID 26226422 DOI: 10.1016/J.Febslet.2015.07.025 |
0.762 |
|
| 2015 |
Bihel F, Humbert JP, Schneider S, Bertin I, Wagner P, Schmitt M, Laboureyras E, Petit-Demoulière B, Schneider E, Mollereau C, Simonnet G, Simonin F, Bourguignon JJ. Development of a peptidomimetic antagonist of neuropeptide FF receptors for the prevention of opioid-induced hyperalgesia. Acs Chemical Neuroscience. 6: 438-45. PMID 25588572 DOI: 10.1021/cn500219h |
0.499 |
|
| 2014 |
Bray L, Froment C, Pardo P, Candotto C, Burlet-Schiltz O, Zajac JM, Mollereau C, Moulédous L. Identification and functional characterization of the phosphorylation sites of the neuropeptide FF2 receptor. The Journal of Biological Chemistry. 289: 33754-66. PMID 25326382 DOI: 10.1074/jbc.M114.612614 |
0.782 |
|
| 2014 |
Journigan VB, Mésangeau C, Vyas N, Eans SO, Cutler SJ, McLaughlin JP, Mollereau C, McCurdy CR. Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors. Journal of Medicinal Chemistry. 57: 8903-27. PMID 25268943 DOI: 10.1021/Jm500989N |
0.367 |
|
| 2014 |
Carayon K, Moulédous L, Combedazou A, Mazères S, Haanappel E, Salomé L, Mollereau C. Heterologous regulation of Mu-opioid (MOP) receptor mobility in the membrane of SH-SY5Y cells. The Journal of Biological Chemistry. 289: 28697-706. PMID 25183007 DOI: 10.1074/jbc.M114.588558 |
0.793 |
|
| 2014 |
Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biological Psychiatry. 76: 767-74. PMID 24629717 DOI: 10.1016/J.Biopsych.2014.01.021 |
0.784 |
|
| 2014 |
Talmont F, Moulédous L, Mollereau C, Zajac JM. Solubilization and reconstitution of the mu-opioid receptor expressed in human neuronal SH-SY5Y and CHO cells. Peptides. 55: 79-84. PMID 24582609 DOI: 10.1016/j.peptides.2014.02.009 |
0.781 |
|
| 2012 |
Gealageas R, Schneider S, Humbert JP, Bertin I, Schmitt M, Laboureyras E, Dugave C, Mollereau C, Simonnet G, Bourguignon JJ, Simonin F, Bihel F. Development of sub-nanomolar dipeptidic ligands of neuropeptide FF receptors. Bioorganic & Medicinal Chemistry Letters. 22: 7471-4. PMID 23131340 DOI: 10.1016/j.bmcl.2012.10.049 |
0.624 |
|
| 2012 |
Talmont F, Moulédous L, Boué J, Mollereau C, Dietrich G. Denatured G-protein coupled receptors as immunogens to generate highly specific antibodies. Plos One. 7: e46348. PMID 23029489 DOI: 10.1371/journal.pone.0046348 |
0.724 |
|
| 2012 |
Mazarguil H, Mollereau C, Czaplicki G, Zajac JM. Study of the N-terminal part of peptidic selective NPFF₂ agonists. Peptides. 37: 157-60. PMID 22813580 DOI: 10.1016/j.peptides.2012.07.008 |
0.35 |
|
| 2012 |
Moulédous L, Froment C, Dauvillier S, Burlet-Schiltz O, Zajac JM, Mollereau C. GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors. The Journal of Biological Chemistry. 287: 12736-49. PMID 22375000 DOI: 10.1074/jbc.M111.314617 |
0.812 |
|
| 2012 |
Najib S, Saint-Laurent N, Estève J, Schulz S, Boutet-Robinet E, Fourmy D, Lättig J, Mollereau C, Pyronnet S, Susini C, Bousquet C. A Switch of G Protein-Coupled Receptor Binding Preference from Phosphoinositide 3-Kinase (PI3K)–p85 to Filamin A Negatively Controls the PI3K Pathway Molecular and Cellular Biology. 32: 1004-1016. PMID 22203038 DOI: 10.1128/Mcb.06252-11 |
0.404 |
|
| 2012 |
Mollereau C, Roumy M, Zajac JM. Neuropeptide FF receptor modulates potassium currents in a dorsal root ganglion cell line. Pharmacological Reports : Pr. 63: 1061-5. PMID 22001995 DOI: 10.1016/s1734-1140(11)70623-5 |
0.368 |
|
| 2011 |
Talmont F, Mollereau C, Zajac JM. Expression of opioid and anti-opioid receptors in Chinese hamster ovary cells after exposure to dimethyl sulfoxide. Analytical Biochemistry. 420: 99-100. PMID 21951781 DOI: 10.1016/j.ab.2011.09.001 |
0.652 |
|
| 2011 |
Kersanté F, Wang JY, Chen JC, Mollereau C, Zajac JM. Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area. Neuroscience Letters. 488: 305-9. PMID 21111027 DOI: 10.1016/J.Neulet.2010.11.052 |
0.514 |
|
| 2010 |
Moulédous L, Mollereau C, Zajac JM. Opioid-modulating properties of the neuropeptide FF system. Biofactors (Oxford, England). 36: 423-9. PMID 20803521 DOI: 10.1002/biof.116 |
0.707 |
|
| 2010 |
Kersanté F, Moulédous L, Zajac JM, Mollereau C. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins. Neurochemistry International. 56: 768-73. PMID 20211672 DOI: 10.1016/j.neuint.2010.02.014 |
0.798 |
|
| 2009 |
Talmont F, Mollereau C, Muller I, Zajac JM. Solubilization and functional reconstitution of human neuropeptide FF2 receptors. Analytical Biochemistry. 398: 225-9. PMID 20018158 DOI: 10.1016/j.ab.2009.12.012 |
0.603 |
|
| 2009 |
Talmont F, Moulédous L, Piedra-Garcia L, Schmitt M, Bihel F, Bourguignon JJ, Zajac JM, Mollereau C. Pharmacological characterization of the mouse NPFF2 receptor. Peptides. 31: 215-20. PMID 19944730 DOI: 10.1016/j.peptides.2009.11.020 |
0.755 |
|
| 2009 |
Talmont F, Garcia LP, Mazarguil H, Zajac JM, Mollereau C. Characterization of two novel tritiated radioligands for labelling Neuropeptide FF (NPFF(1) and NPFF(2)) receptors. Neurochemistry International. 55: 815-9. PMID 19682524 DOI: 10.1016/j.neuint.2009.08.004 |
0.416 |
|
| 2008 |
Moulédous L, Merker S, Neasta J, Roux B, Zajac J, Mollereau C. Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells Biochemical and Biophysical Research Communications. 373: 80-84. PMID 18544342 DOI: 10.1016/J.Bbrc.2008.05.174 |
0.783 |
|
| 2007 |
Mollereau C, Zajac JM, Roumy M. Staurosporine differentiation of NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells induces selectivity of NPFF activity towards opioid receptors. Peptides. 28: 1125-8. PMID 17418451 DOI: 10.1016/j.peptides.2007.03.001 |
0.651 |
|
| 2007 |
Roumy M, Lorenzo C, Mazères S, Bouchet S, Zajac JM, Mollereau C. Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity. The Journal of Biological Chemistry. 282: 8332-42. PMID 17224450 DOI: 10.1074/jbc.M606946200 |
0.7 |
|
| 2006 |
Vyas N, Mollereau C, Chevé G, McCurdy CR. Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives. Peptides. 27: 990-6. PMID 16490282 DOI: 10.1016/J.Peptides.2005.07.024 |
0.379 |
|
| 2006 |
Kersanté F, Mollereau C, Zajac JM, Roumy M. Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides. 27: 980-9. PMID 16488058 DOI: 10.1016/j.peptides.2005.07.025 |
0.637 |
|
| 2006 |
Simonin F, Schmitt M, Laulin JP, Laboureyras E, Jhamandas JH, MacTavish D, Matifas A, Mollereau C, Laurent P, Parmentier M, Kieffer BL, Bourguignon JJ, Simonnet G. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proceedings of the National Academy of Sciences of the United States of America. 103: 466-71. PMID 16407169 DOI: 10.1073/Pnas.0502090103 |
0.561 |
|
| 2005 |
Roussin A, Serre F, Gouardères C, Mazarguil H, Roumy M, Mollereau C, Zajac JM. Anti-analgesia of a selective NPFF2 agonist depends on opioid activity. Biochemical and Biophysical Research Communications. 336: 197-203. PMID 16129413 DOI: 10.1016/J.Bbrc.2005.08.060 |
0.623 |
|
| 2005 |
Mollereau C, Roumy M, Zajac JM. Opioid-modulating peptides: mechanisms of action. Current Topics in Medicinal Chemistry. 5: 341-55. PMID 15857316 DOI: 10.2174/1568026053544515 |
0.441 |
|
| 2004 |
Mollereau C, Mazarguil H, Zajac JM, Roumy M. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Molecular Pharmacology. 67: 965-75. PMID 15608144 DOI: 10.1124/mol.104.004614 |
0.653 |
|
| 2002 |
Mollereau C, Mazarguil H, Marcus D, Quelven I, Kotani M, Lannoy V, Dumont Y, Quirion R, Detheux M, Parmentier M, Zajac JM. Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. European Journal of Pharmacology. 451: 245-56. PMID 12242085 DOI: 10.1016/S0014-2999(02)02224-0 |
0.606 |
|
| Show low-probability matches. |